Guardant and MSD will evaluate opportunities to develop new oncology therapies using liquid biopsy tests.

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price for the business, which has a cancer-focused pipeline headed by ...

BDT & MSD Partners provided an additional $55 million loan to OKO Group and Cain International for their planned Palm Beach ...

A higher dose of anti-T-lymphocyte globulin (ATLG) significantly outperformed a lower dose in preventing graft-vs-host ...

Monroe County Community Schools - closed, with eLearning. Teachers/schools will communicate information via Canvas and ...

A study of 50,000+ health searches found Google’s AI Overviews cited YouTube more than any hospital, clinic, or health agency ...

MSD and the Coalition for Epidemic Preparedness Innovations have launched a $30 million initiative to improve the ...

SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration ...

It comes as food charities call for urgent ongoing government funding as they face unprecedented demand during the cost of ...

Related Ross, led by billionaire and Miami Dolphins owner Stephen Ross, bought 71% of a 45-year-old condo complex in West ...